

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group’s Pentoxifylline, Levornidazole and Ornidazole have obtained the approvals for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market, in which Pentoxifylline being the second one and Levornidazole being the third one of such approvals for the PRC entities.

Pentoxifylline is mainly used for the treatment of peripheral vascular disease and cerebrovascular insufficiency. Levornidazole is the levo-isomer of Ornidazole. Levornidazole and Ornidazole are mainly used for the treatment of various infections caused by susceptible anaerobic bacteria.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 27 May 2022

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.